ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have earned an average recommendation of “Moderate Buy” from the six analysts that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $2.50.

A number of equities analysts have commented on ALXO shares. Jefferies Financial Group began coverage on shares of ALX Oncology in a research note on Thursday, November 13th. They issued a “buy” rating and a $4.00 price target for the company. Wall Street Zen raised shares of ALX Oncology from a “sell” rating to a “hold” rating in a report on Monday, December 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of ALX Oncology in a research note on Wednesday, January 21st. Finally, Piper Sandler raised their price target on ALX Oncology from $3.00 to $4.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th.

Insiders Place Their Bets

In other news, Director Corey S. Goodman bought 3,184,713 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was bought at an average price of $1.57 per share, for a total transaction of $4,999,999.41. Following the transaction, the director directly owned 8,453,038 shares of the company’s stock, valued at $13,271,269.66. This represents a 60.45% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 21.00% of the stock is owned by insiders.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Bridgeway Capital Management LLC purchased a new stake in shares of ALX Oncology in the 3rd quarter valued at $66,000. Invesco Ltd. purchased a new position in ALX Oncology in the 1st quarter worth $46,000. Seven Fleet Capital Management LP bought a new stake in ALX Oncology in the fourth quarter worth $133,000. AQR Capital Management LLC boosted its position in ALX Oncology by 183.6% during the first quarter. AQR Capital Management LLC now owns 119,050 shares of the company’s stock valued at $74,000 after buying an additional 77,065 shares during the period. Finally, State Street Corp boosted its position in ALX Oncology by 11.0% during the fourth quarter. State Street Corp now owns 124,228 shares of the company’s stock valued at $140,000 after buying an additional 12,300 shares during the period. 97.97% of the stock is owned by hedge funds and other institutional investors.

ALX Oncology Stock Performance

NASDAQ:ALXO opened at $2.11 on Friday. The stock has a market cap of $114.40 million, a P/E ratio of -1.04 and a beta of 0.51. The company has a quick ratio of 2.40, a current ratio of 2.40 and a debt-to-equity ratio of 0.13. The business’s 50-day moving average price is $1.70 and its two-hundred day moving average price is $1.50. ALX Oncology has a twelve month low of $0.40 and a twelve month high of $2.66.

ALX Oncology (NASDAQ:ALXO) last issued its quarterly earnings data on Friday, February 27th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.04). As a group, equities analysts predict that ALX Oncology will post -2.76 EPS for the current fiscal year.

About ALX Oncology

ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.

The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.